Clinical trial
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
NCT03082729 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
- Lead sponsor
- University of Pennsylvania
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 24, 2017
- Completion date
- August 17, 2021
- Enrollment
- 70 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.